Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • PR Newswire Amplify™
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • IR
  • All Products
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Sign Up
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media Enquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR

Public advisory - Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks Français


News provided by

Health Canada (HC)

Dec 24, 2025, 11:45 ET

Share this article

Share toX

Share this article

Share toX

OTTAWA, ON, Dec. 24, 2025 /CNW/ - 

Summary

  • Product: Unauthorized drugs, including injectable peptides and controlled drugs
  • Issue: Health products – Unauthorized product; Product safety
  • What to do: Do not use these products. Consult a licensed health care professional if you have used these products and have health concerns. Do not buy or use unauthorized drugs. Only buy prescription drugs from licensed pharmacies.

Affected products

Unauthorized health products seized from Rize Fitness (188 Smithe St, Vancouver, BC) and sold online, including:

Category

Product name

Injectable peptide drugs

PHX Labs Semaglutide (5mg and 10mg)

PHX Labs AOD-9604 5mg

PHX Labs CJC-1295 5MG

PHX Labs Epithalon 10MG

PHX Labs GHK-CU 50 MG

PHX Labs Glow 70 MG (BPC 10mg/TB-500 10mg/GHK-Cu 50mg)

PHX Labs Ipamorelin 10 MG

PHX Labs Kisspeptin-10MG

PHX Labs Klow 80 MG (BPC 10mg/TB-500 10mg/GHK-Cu 50mg/KPV 10mg)

PHX Labs MOTS-C (10 MG and 40MG)

PHX Labs SS-31 10 MG

PHX Labs TB-500 10mg

PHX Labs Tesamorelin 10mg

PHX Labs Thymosin Alpha-1 10 MG

PHX Labs Retatrutide 5mg

PHX Labs Melanotan-2 10 MG

PHX Labs CJC-1295 DAC 5 MG

PHX Labs DSIP 5 MG

PHX Labs 5-AMINO-IMQ 5 MG

PHX Labs SLU-PP-332

PHX Labs HGH Somatropin (12IU and 15IU)

PHX Labs BPC-157

Injectable testosterone compound

PHX Labs Testosterone Cypionate USP 250 MG/ML

Prescription drugs

PHX Labs D3 10,000 WITH K2

Controlled drugs

NutriDyn DHEA 25mg

Issue

Health Canada is warning consumers about multiple unauthorized health products seized from Rize Fitness located at 188 Smithe Street, in Vancouver, British Columbia, and sold through the website phxlab.net. Health Canada has not authorized any of the products that were seized or sold on the website, which means that they have not been assessed for safety, efficacy, and quality. Selling unauthorized health products in Canada is illegal. At Health Canada's request, the company has stopped advertising and selling unauthorized health products, including taking down its website.

The seized products are labeled to contain prescription, controlled, or other drug ingredients and many are in injectable form. The products include injectable peptides and testosterone compounds, often used for bodybuilding, anti-aging, enhancing athletic performance or weight loss. Many injectable peptides are regulated as prescription drugs in Canada.

Unauthorized drugs may:

  • Interact with other medications an individual might be taking.
  • Contain high-risk ingredients, additives, or contaminants that may or may not be listed on the label.
  • Not have been manufactured or stored safely.

Prescription drugs should only be used under the care of a healthcare professional because they are used to treat specific conditions and may cause serious side effects. Injectable unauthorized drugs carry additional risks, including infections, allergic reactions, and other serious adverse outcomes due to contamination, improper handling, or unsafe administration.

Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed.

What you should do

  • Do not use these products. Consult a health care professional if you have used unauthorized health products and have health concerns.
  • Only buy prescription drugs from licensed pharmacies.
  • Do not buy or use unauthorized drugs. Read product labels to confirm a product has been authorized for sale by Health Canada. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products have been authorized for sale by searching Health Canada's Drug Product Database and Licensed Natural Health Product Database.
  • Follow municipal or regional guidelines on disposing chemicals and other hazardous waste or return the product to your local pharmacy for proper disposal.
  • Report any health product-related side effects or complaints to Health Canada.
  • Learn more about buying health products safely:
    • Buying drugs over the Internet
    • Adulteration of natural health products
    • Risks of buying natural health products online
    • The safe use of health products for weight loss
    • Safe Use of Bodybuilding Products - Canada.ca

Additional information

Background

In addition to the general information above, Health Canada is providing additional safety information for certain products to provide consumers with more information about the risks they may be exposed to when taking unauthorized health products purchased from Rize Fitness and from the phxlab.net website. 

Dehydroepiandrosterone (DHEA) is a controlled substance regulated under the Controlled Drugs and Substances Act. It can cause higher-than-normal levels of female and male hormones in the body and could increase the risk of prostate, breast and other hormone-sensitive cancers. Potential side effects include serious cardiovascular disease, and changes in fertility and sperm production. DHEA might cause acne and male-pattern hair growth in women (hirsutism). DHEA should be avoided by individuals with a history of abnormal heart rhythms, blood clotting disorders, liver disease, have known or suspected hormone-dependent cancers, have a history of hormone-sensitive disorders unless under medical supervision, and during pregnancy or breastfeeding. DHEA also might worsen psychiatric disorders and increase the risk of mania in people who have mood disorders due to drug interactions with antipsychotics and other mood disorder medications. Unauthorized DHEA products have not been evaluated by Health Canada and may pose serious safety risks. 

Semaglutide is available by prescription only in Canada and can be in found in either injectable form or as an oral tablet. Semaglutide is generally well tolerated, but it can be associated with significant risks, which include gastrointestinal side effects, pancreatitis, worsening kidney function, hypoglycemia (when combined with other diabetes drugs), potential thyroid tumours, diabetic retinopathy complications, hypersensitivity reactions, and delayed gastric emptying that may pose risks if the patient is undergoing a procedure which requires sedation.

Testosterone compounds, such as testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone canoate, testosterone enanthate, and testosterone decanoate, are synthetic anabolic steroids. They have been linked to many significant health risks, some of which are permanent and even fatal. These compounds can cause serious side effects, including heart problems, fluid retention, mood changes, sleep and breathing issues, kidney damage, digestive upset, muscle and joint pain, and high blood fat levels. In men, they may lead to infertility, reduced testicle size, breast enlargement, and prostate issues. In women, they may cause male characteristics such as facial hair, a deeper voice, and hair loss. In children, they can disrupt normal growth and puberty. Accidental exposure in children can cause early sexual development. They may also be habit-forming. These compounds should not be used by people with cancer, heart or kidney disease, high blood pressure, diabetes, or a history of stroke or blood clots, and they must not be used during pregnancy or breastfeeding.

SOURCE Health Canada (HC)

Media Enquiries: Health Canada, (613) 957-2983, [email protected]; Public Enquiries: (613) 957-2991, 866 225-0709, [email protected]

Modal title

Organization Profile

Health Canada (HC)

    Also from this source

  • Public Advisory - Unlicensed Chroma D-Light UV Lamp May Pose Health Risks

  • Health Canada Opens Formal Consultations on Red Tape Reduction Initiatives to Improve Access to Drugs

  • Health Canada acts to prevent misuse and diversion of precursor chemicals and drug equipment

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Platform Login
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.